Los Angeles, California-based Puma Biotechnology has shuffled a challenging new drug application (NDA) onto FDA’s desk.
Neratinib has polarized experts and investors over the last few weeks, with its data flaws and dubious benefit-to-risk ratio. The drug is currently under review for use in breast cancer patients who have had their tumors surgically removed.
